Precision Immunotherapies for Solid Tumors Built on Functional Biology at the Single-Cell Level
We develop precision immunotherapies for solid tumors through an integrated technology platform spanning target discovery, ultra-high-throughput microfluidics-driven functional screening, computational binder design and predictive safety assessment.
We develop both antibody-based and TCR-based T-cell engagers designed to address surface and intracellular cancer targets. Our initial oncology pipeline includes programs in small cell lung cancer, ovarian cancer and hepatocellular carcinoma.
Powered by Our Unified Engine
Where conventional discovery tests binders sequentially over months, our TCELERATORTM platform profiles more than 10 million single-cell interactions at once, identifying functional leads in a single experiment, with a hit rate of >80%. We further combine this platform with computational biology and translational immunology into a unified engine to develop more selective and safer molecules, starting with next-generation T-cell engagers.
This biology-driven approach is supported by proprietary human tumor datasets built through an expanding network of academic and clinical collaborators across 15 institutions, and 8,000 square feet of laboratory and office space in San Francisco near UCSF Mission Bay.
Centered around people
We believe that people are the key that drives scientific and organizational successes. We are dedicated to building an environment where everyone thrives. We have a culture of collaboration, ownership, and authenticity. We are proud to have built an interdisciplinary team that embodies this culture.
.png)
Latest News
Finding The Therapeutic Window: Using Single-Cell Biology To Build More Selective T-Cell Engagers
Read Article
Shennon Biotechnologies announces a new CEO, Cyril Konto, and a $12M raise for its T-cell engager programs
Read Article
Shennon Biotechnologies Raises $12M in Financing, Appoints Cyril Konto, M.D., as Chief Executive Officer and Unveils Precision Immunotherapy Pipeline
Read Article
Shennon Biotechnologies Raises $12M in Financing, Appoints Cyril Konto, M.D., as Chief Executive Officer and Unveils Precision Immunotherapy Pipeline
Read Article
Shennon Biotechnologies Raises $12 Million, Names Cyril Konto As CEO, And Unveils Precision Immunotherapy Pipeline
Read Article
ShennonBio Founder Dr. Li Sun serves as a panelist at SITC's Women in Cancer Immunotherapy Leadership Institute
Read Article
How a onetime VC came back to science to focus on finding better targets faster against cancer
Read Article
Shennon Biotechnologies Raises $13M Seed Financing to Accelerate Immunotherapy Target Discovery with Proprietary Single-Cell Functional Screening Platform
Read Article
Work with Us to Cure the Incurable
